Get the Stockscreener App
1.19
0.00%
0.00
Biocardia Inc stock is traded at $1.19, with a volume of 19,648.
It is up +0.00% in the last 24 hours and down -4.03% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.19
Open:
$1.22
24h Volume:
19,648
Relative Volume:
0.26
Market Cap:
$12.77M
Revenue:
$3,000
Net Income/Loss:
$-8.54M
P/E Ratio:
-0.6898
EPS:
-1.7252
Net Cash Flow:
$-7.51M
1W Performance:
-4.03%
1M Performance:
-4.03%
6M Performance:
-42.23%
1Y Performance:
-53.15%
1-Day Range:
$1.19
$1.23
1-Week Range:
$1.135
$1.3861
52-Week Range:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.1602 | 2.87B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
7.16 | 465.95M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.18 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.94 | 350.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
45.21 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) - Bitget
BioCardia Highlights Positive CardiAMP Phase III Heart Failure Data - TipRanks
BioCardia reports positive echocardiography results from Phase III CardiAMP HF trial indicating reduced ventricular remodeling - TradingView
New CardiAMP HF echo data from BioCardia (NASDAQ: BCDA) highlight ventricular remodeling - Stock Titan
Heart failure cell therapy shows less adverse cardiac remodeling - Stock Titan
BCDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BCDA Should I Buy - Intellectia AI
Loss Report: Can BioCardia Inc ride the EV wavePortfolio Profit Report & Daily Growth Stock Tips - baoquankhu1.vn
Chipmakers Recap: Does BioCardia Inc have pricing powerQuarterly Performance Summary & Fast Gaining Stock Reports - baoquankhu1.vn
S P Trends: Can BioCardia Inc. ride the EV waveMarket Trend Review & Verified Short-Term Plans - mfd.ru
BCDA PE Ratio & Valuation, Is BCDA Overvalued - Intellectia AI
How is BioCardia Inc. managing supply chain issuesMarket Volume Summary & Weekly Top Performers Watchlists - mfd.ru
Biocardia's Regulatory Milestone: FDA Submission Paves Way for Cardiac Delivery System () - aktiencheck.de
BioCardia submits FDA pre-submission for heart delivery catheter By Investing.com - Investing.com Nigeria
Biocardia files pre-submission for FDA approval of Helix(TM) - marketscreener.com
BioCardia (BCDA) Advances Helix Catheter Approval with FDA Pre-S - GuruFocus
BioCardia submits FDA pre-submission for heart delivery catheter - Investing.com
BioCardia Advances FDA Pathway for Helix Delivery Catheter - TipRanks
BioCardia Submits Pre-Submission to FDA for Helix Transendocardial Delivery Catheter Approval - Quiver Quantitative
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart - marketscreener.com
BioCardia Files Pre-Submission for FDA Approval of Helix™ - GlobeNewswire
Catheter to deliver cell and gene therapies to the heart heads to FDA - Stock Titan
Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus
BioCardia’s CardiAMP Heart Failure Data Selected for LBCT - TipRanks
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) - The Manila Times
BioCardia, Inc. Announces Presentation of CardiAMP HF Trial Data - TradingView
Heart failure cell therapy trial lands late-breaking THT slot for echo data - stocktitan.net
Insider Sell: Will Matador Resources Company benefit from geopolitical trendsDividend Hike & Weekly Momentum Stock Picks - baoquankhu1.vn
Activity Recap: Does BioCardia Inc have consistent dividend growthQuarterly Trade Review & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aug Ideas: Whats Sono Tek Corporations historical returnPortfolio Value Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Chipmakers Recap: Should you avoid BioCardia Inc stock right now2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36% - Intellectia AI
Altman Peter buys BioCardia (BCDA) shares worth $1,194 By Investing.com - Investing.com Nigeria
Altman Peter buys BioCardia (BCDA) shares worth $1,194 - Investing.com
Trend Review: Is BioCardia Inc. in a long term uptrendWeekly Investment Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
US Stocks Recap: Can BioCardia Inc expand its profit marginsJuly 2025 Big Picture & Weekly Chart Analysis and Guides - baoquankhu1.vn
Swing Trade: Is BioCardia Inc stock forming a triangle patternGap Up & High Accuracy Trade Alerts - baoquankhu1.vn
Can BioCardia Inc. stock deliver surprise earnings beat2025 Buyback Activity & AI Enhanced Trade Execution Alerts - Bộ Nội Vụ
Published on: 2026-01-10 18:46:33 - Улправда
Will BioCardia Inc. (6JU0) stock keep high P E multiplesPortfolio Return Report & Reliable Entry Point Alerts - Улправда
Can BioCardia Inc. stock continue upward trendWeekly Stock Report & AI Optimized Trading Strategy Guides - Улправда
Forecast Cut: Will BioCardia Inc. stock rally after Fed decisionsJuly 2025 Weekly Recap & Daily Entry Point Alerts - ulpravda.ru
Will BioCardia Inc. stock rally after Fed decisionsMarket Activity Report & Community Trade Idea Sharing Platform - Улправда
How BioCardia Inc. stock reacts to bond yields2026 world cup usa national team qualification midfield engines set piece tactics expert forecast analysis - Улправда
Bull Run: Why analysts raise outlook for BioCardia Inc 6JU0 stock2025 Market Outlook & Daily Profit Focused Stock Screening - moha.gov.vn
Profit Review: Will BioCardia Inc 6JU0 stock sustain uptrend momentumJuly 2025 Volume & Safe Capital Growth Stock Tips - moha.gov.vn
Is BioCardia Inc 6JU0 a good long term investmentEconomic Indicators Overview & Free Stay Ahead With Picks - earlytimes.in
BioCardia (BCDA) Stock Analysis Report | Financials & Insights - Benzinga
BioCardia advances CardiAMP therapy in Japan - MSN
Will BioCardia Inc. stock deliver long term returns2025 Technical Patterns & Daily Growth Stock Tips - Улправда
Will BioCardia Inc. stock keep outperforming rivals2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Jan 20 '26 |
Buy |
1.32 |
600 |
792 |
268,566 |
| Altman Peter | President and CEO |
Jan 21 '26 |
Buy |
1.34 |
300 |
402 |
268,866 |
| Altman Peter | President and CEO |
Dec 17 '25 |
Buy |
1.30 |
900 |
1,170 |
267,966 |
| Altman Peter | President and CEO |
Dec 16 '25 |
Buy |
1.37 |
200 |
274 |
267,066 |
| STERTZER SIMON H | Director |
Sep 19 '25 |
Buy |
1.25 |
398,400 |
498,000 |
591,054 |
| Blank Andrew Scott | Director |
Sep 19 '25 |
Buy |
1.25 |
288,000 |
360,000 |
634,023 |
| Altman Peter | President and CEO |
Sep 19 '25 |
Buy |
1.25 |
48,000 |
60,000 |
216,762 |
| Altman Peter | President and CEO |
Aug 22 '25 |
Buy |
1.83 |
700 |
1,281 |
168,762 |
| Altman Peter | President and CEO |
Aug 13 '25 |
Buy |
1.83 |
100 |
183 |
168,062 |
| Altman Peter | President and CEO |
Aug 12 '25 |
Buy |
1.75 |
400 |
700 |
167,962 |
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):